Baptist Health International Conference Series: Past, Present and Future of Genetic Cancer Risk Assessment - July 2017 Evaluation

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1
Identify appropriate patients to refer for a genetic cancer risk assessment (GCRA).	Identify appropriate patients to refer for a genetic cancer risk assessment (GCRA). - 5	Identify appropriate patients to refer for a genetic cancer risk assessment (GCRA). - 4	Identify appropriate patients to refer for a genetic cancer risk assessment (GCRA). - 3	Identify appropriate patients to refer for a genetic cancer risk assessment (GCRA). - 2	Identify appropriate patients to refer for a genetic cancer risk assessment (GCRA). - 1
Explain the GCRA process and recognize the changing landscape of genetic testing – syndrome-driven versus multi-gene panels.	Explain the GCRA process and recognize the changing landscape of genetic testing – syndrome-driven versus multi-gene panels. - 5	Explain the GCRA process and recognize the changing landscape of genetic testing – syndrome-driven versus multi-gene panels. - 4	Explain the GCRA process and recognize the changing landscape of genetic testing – syndrome-driven versus multi-gene panels. - 3	Explain the GCRA process and recognize the changing landscape of genetic testing – syndrome-driven versus multi-gene panels. - 2	Explain the GCRA process and recognize the changing landscape of genetic testing – syndrome-driven versus multi-gene panels. - 1
Summarize the benefits and limitations of surveillance and risk management options for cancer predisposition syndrome.	Summarize the benefits and limitations of surveillance and risk management options for cancer predisposition syndrome. - 5	Summarize the benefits and limitations of surveillance and risk management options for cancer predisposition syndrome. - 4	Summarize the benefits and limitations of surveillance and risk management options for cancer predisposition syndrome. - 3	Summarize the benefits and limitations of surveillance and risk management options for cancer predisposition syndrome. - 2	Summarize the benefits and limitations of surveillance and risk management options for cancer predisposition syndrome. - 1

Rate the following *

Scoring Key: 5=Excellent 4=Very Good 3=Good 2=Fair 1=Poor

	5	4	3	2	1
Course content.	Course content. - 5	Course content. - 4	Course content. - 3	Course content. - 2	Course content. - 1
Arelis E. Martir-Negron, M.D., FACMG	Arelis E. Martir-Negron, M.D., FACMG - 5	Arelis E. Martir-Negron, M.D., FACMG - 4	Arelis E. Martir-Negron, M.D., FACMG - 3	Arelis E. Martir-Negron, M.D., FACMG - 2	Arelis E. Martir-Negron, M.D., FACMG - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

What do you intend to do differently in the treatment of your patients as a result of what you learned? What new strategies will you apply in your practice of patient care? *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so. *

Comments

Name

You are here

Baptist Health International Conference Series: Past, Present and Future of Genetic Cancer Risk Assessment - July 2017 Evaluation